ArticleInternational journal of clinical and experimental pathology2017
Luteolin suppresses tumor progression through lncRNA BANCR and its downstream TSHR/CCND1 signaling in thyroid carcinoma.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Natural product-based interventions for thyroid disorders: mechanisms and applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Investigating the potential anti-cancer mechanism for thyroid cancer: Role of Herba Epimedii via network pharmacology approach.Journal, genetic engineering & biotechnology · 2025Article
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- Inhibitory effect of luteolin on the metabolism of vandetanibFrontiers in pharmacology · 2025Article
- Research progress of plant-derived natural products in thyroid carcinoma.Frontiers in chemistry · 2023Review
- Review
- Regulation of Long Non-Coding RNAs by Plant Secondary Metabolites: A Novel Anticancer Therapeutic Approach.Cancers · 2021Review
- The Emerging Landscapes of Long Noncoding RNA in Thyroid Carcinoma: Biological Functions and Clinical Significance.Frontiers in oncology · 2021Review
- Role of lncRNA BANCR in Human Cancers: An Updated Review.Frontiers in cell and developmental biology · 2021Review
- Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review.Cancer cell international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The flavonoid luteolin is a natural antioxidant that usually occurs in its glycosylated form in many green vegetables, and has shown anticancer effects against various cancers. However, the potential tumor-suppressive role of luteolin in thyroid carcinoma and its underlying mechanism remain largely unknown. In current study, SBR assay, clone formation assay were employed to evaluate the effects of luteolin on thyroid cancer. We found that luteolin significantly inhibits thyroid cancer growth. The further mechanisms of its anticancer activity were analyzed by flow cytometry, quantitative real-time PCR, and Western blotting. We found that luteolin decreased the expression of BRAF-activated long noncoding RNA (BANCR), which further led to downregulation of TSHR and downstream oncogenic signaling. Moreover, overexpression of BANCR/TSHR signaling can largely abolish the anti-tumor effects of luteolin on thyroid carcinoma in vitro and in vivo. In conclusion, luteolin may serve as a potential important anticancer agent for thyroid carcinoma by blocking the BANCR/TSHR signaling.
Indexed as
Identifiers
31966836PMC6965909W3004896884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.